Serological Surveillance of Betacoronaviruses in Bat Guano Collectors: Pre-COVID-19 Pandemic and Post-SARS-CoV-2 Emergence.

Publication date: Jun 10, 2025

Community-based serosurveillance for emerging zoonotic viruses can provide a powerful and cost-effective measurement of cryptic spillovers. Betacoronaviruses, including SARS-CoV, SARS-CoV-2 and MERS-CoV, are known to infect bats and can cause severe respiratory illness in humans, yet remain under-surveyed in high-risk populations. This study aimed to determine the seroprevalence of betacoronaviruses in an occupational cohort in contact with bats before and after the emergence of SARS-CoV-2. Serum samples from pre- and post-COVID-19 pandemic were screened using antigen-based multiplex microsphere immunoassays (MMIAs) and a multiplex surrogate virus neutralization test (sVNT). Pre-pandemic samples showed no SARS-CoV-2 antibodies, while post-pandemic samples from vaccinated participants displayed binding and neutralizing antibodies against SARS-CoV-2 and a related bat CoV. Furthermore, one participant (1/237, 0. 43%) had persistent antibodies against MERS-CoV in 2017, 2018 and 2021 but was seronegative in 2023, despite reporting no history of traveling abroad or severe pneumonia. The observed sustained antibody levels indicate a possible exposure to MERS-CoV or a MERS-CoV-like virus, although the etiology and clinical relevance of this finding remains unclear. Ongoing surveillance in high-risk populations remains crucial for understanding virus epidemiology and mitigating zoonotic transmission risk.

Open Access PDF

Concepts Keywords
Bat Adult
Betacoronaviruses Animals
Pneumonia Antibodies, Neutralizing
Severe Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
betacoronaviruses
binding antibodies
Chiroptera
COVID-19
COVID-19
Female
Humans
Male
Middle Aged
Pandemics
SARS-CoV-2
SARS-CoV-2
Seroepidemiologic Studies
surrogate neutralizing antibodies
Zoonoses
zoonotic spillovers

Semantics

Type Source Name
disease MESH COVID-19 Pandemic
disease IDO history
disease MESH pneumonia
disease MESH etiology
disease MESH clinical relevance
drug DRUGBANK Etodolac
disease MESH Emerging Infectious Diseases
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH zoonotic spillovers
disease MESH Middle East respiratory syndrome
disease MESH emergency
drug DRUGBANK Activated charcoal
drug DRUGBANK Nitrogen
drug DRUGBANK Phosphorus
drug DRUGBANK Methionine
drug DRUGBANK Etoperidone
drug DRUGBANK Trestolone
disease IDO blood
disease MESH infection
disease IDO process
disease IDO assay
drug DRUGBANK Phosphate ion
drug DRUGBANK Immune Globulin Human
disease IDO nucleic acid
drug DRUGBANK Magnesium
drug DRUGBANK Choline
drug DRUGBANK Platinum
drug DRUGBANK Water
disease IDO production
disease IDO site
disease IDO protein
disease IDO zoonosis
disease MESH common cold
disease MESH seroconversion
disease MESH influenza
disease IDO host
disease IDO infectivity
disease MESH Allergy
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Caffeine
drug DRUGBANK Sodium hydroxide
drug DRUGBANK Guanosine

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *